Important Safety InformationWarning and PrecautionsInfusion ReactionsInfusion reactions, including hypersensitivity reactions and anaphylaxis, may occur. Monitor during administration and for at least 3 hours after end of infusion. If symptoms occur, slow or interrupt administration. Re-start administration at a slower infusion once resolved. Hepatotoxicity/Hepatocellular CarcinomaPost-dose, monitor for elevated transaminase levels. Consider corticosteroid treatment should elevations occur. The integration of liver-targeting AAV vector DNA into the genome may carry the theoretical risk of hepatocellular carcinoma development. For patients with preexisting risk factors for hepatocellular carcinogenicity, perform regular (eg, annual) abdominal ultrasound and alpha-fetoprotein testing following administration. Immune-mediated neutralization of the AAV5 vector capsidPreexisting neutralizing anti-AAV antibodies may impede transgene expression at desired levels. Monitoring Laboratory TestsIn addition to monitoring liver function, monitor for Factor IX activity and Factor IX inhibitors after administration. Adverse ReactionsThe most common adverse reactions (incidence ≥5%) were elevated ALT, headache, blood creatine kinase elevations, flu-like symptoms, infusion-related reactions, fatigue, nausea, malaise, and elevated AST. IndicationHEMGENIX is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: - Currently use Factor IX prophylaxis therapy, or
- Have current or historical life-threatening hemorrhage, or
- Have repeated, serious spontaneous bleeding episodes.
|
HEMGENIX is for single use intravenous infusion only. Contraindications: None. Please see full prescribing information for HEMGENIX. To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. | 
